Skip to main content
SpringerLink
Log in

Gastrointestinal Neuroendocrine Tumors: Optimal Outcomes and Surgical Management

  • Chapter
Current Controversies in Cancer Care for the Surgeon

  • 834 Accesses

Abstract

Neuroendocrine tumors (NETs) are a specific type of neoplasm arising in tissues of neural crest origin. They commonly arise in the gastrointestinal tract because of the high density of neuroendocrine cells, and are found in the foregut (stomach, duodenum, pancreas), midgut (jejunum, ileum, appendix, proximal colon), and hindgut (distal colon, rectum). NETs are commonly termed “carcinoid” tumors if they are found to be of low grade on histology. The prognosis for NETs is variable, dependent upon tumor biology and origin. This chapter reviews specific features of NETs in each GI segment, with particular focus on factors predicting prognosis and surgical decision-making.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Oberndorfer S. Karzinoide tumoren des du¨nndarms. Frankf Z Pathol. 1907;1:426–9.

    Google Scholar 

  2. Kloppel G, Anlauf M. Epidemiology, tumour biology and histopathological classification of neuroendocrine tumours of the gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2005;19(4):507–17.

    Article  PubMed  Google Scholar 

  3. Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004;80 Suppl 1:3–7.

    Article  PubMed  CAS  Google Scholar 

  4. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.

    Article  PubMed  Google Scholar 

  5. Rindi G, Kloppel G, Couvelard A, Komminoth P, Korner M, Lopes JM, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451(4):757–62.

    Article  PubMed  CAS  Google Scholar 

  6. Rindi G. The ENETS guidelines: the new TNM classification system. Tumori. 2010;96(5):806–9.

    PubMed  Google Scholar 

  7. Sobin LH, Compton CC. TNM seventh edition: what’s new, what’s changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer. 2010;116(22):5336–9.

    Article  PubMed  Google Scholar 

  8. Solcia E, Klöppel G, Sobin LH. Histological typing of endocrine tumors. WHO international histological classification of tumors. 2nd ed. Berlin: Springer; 2000. p. 56–70.

    Book  Google Scholar 

  9. John M, Meyerhof W, Richter D, Waser B, Schaer JC, Scherubl H, et al. Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut. 1996;38(1):33–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Binderup T, Knigge U, Loft A, Mortensen J, Pfeifer A, Federspiel B, et al. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med. 2010;51(5):704–12.

    Article  PubMed  Google Scholar 

  11. Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16(3):978–85.

    Article  PubMed  CAS  Google Scholar 

  12. Oberg K, Castellano D. Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer Metastasis Rev. 2011;30 Suppl 1:3–7.

    Article  PubMed  CAS  Google Scholar 

  13. Pettinato C, Sarnelli A, Di Donna M, Civollani S, Nanni C, Montini G, et al. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2008;35(1):72–9.

    Article  PubMed  CAS  Google Scholar 

  14. Baldelli R, Barnabei A, Rizza L, Isidori AM, Rota F, Di Giacinto P, et al. Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives. Front Endocrinol. 2014;5:7.

    Article  Google Scholar 

  15. Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15(6):966–73.

    Article  PubMed  CAS  Google Scholar 

  16. Schally AV. Oncological applications of somatostatin analogues. Cancer Res. 1988;48(24 Pt 1):6977–85.

    PubMed  CAS  Google Scholar 

  17. Lawnicka H, Stepien H, Wyczolkowska J, Kolago B, Kunert-Radek J, Komorowski J. Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture. Biochem Biophys Res Commun. 2000;268(2):567–71.

    Article  PubMed  CAS  Google Scholar 

  18. Annibale B, Lahner E, Fave GD. Diagnosis and management of pernicious anemia. Curr Gastroenterol Rep. 2011;13(6):518–24.

    Article  PubMed  Google Scholar 

  19. Lahner E, Norman GL, Severi C, Encabo S, Shums Z, Vannella L, et al. Reassessment of intrinsic factor and parietal cell autoantibodies in atrophic gastritis with respect to cobalamin deficiency. Am J Gastroenterol. 2009;104(8):2071–9.

    Article  PubMed  CAS  Google Scholar 

  20. Borch K, Ahren B, Ahlman H, Falkmer S, Granerus G, Grimelius L. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg. 2005;242(1):64–73.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Jordan Jr PH, Barroso A, Sweeney J. Gastric carcinoids in patients with hypergastrinemia. J Am Coll Surg. 2004;199(4):552–5.

    Article  PubMed  Google Scholar 

  22. Norton JA, Melcher ML, Gibril F, Jensen RT. Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery. 2004;136(6):1267–74.

    Article  PubMed  Google Scholar 

  23. Nikou GC, Toubanakis C, Moulakakis KG, Pavlatos S, Kosmidis C, Mallas E, et al. Carcinoid tumors of the duodenum and the ampulla of Vater: current diagnostic and therapeutic approach in a series of 8 patients. Case series. Int J Surg. 2011;9(3):248–53.

    Article  PubMed  Google Scholar 

  24. Zyromski NJ, Kendrick ML, Nagorney DM, Grant CS, Donohue JH, Farnell MB, et al. Duodenal carcinoid tumors: how aggressive should we be? J Gastrointest Surg. 2001;5(6):588–93.

    Article  PubMed  CAS  Google Scholar 

  25. Waisberg J, Joppert-Netto G, Vasconcellos C, Sartini GH, Miranda LS, Franco MI. Carcinoid tumor of the duodenum: a rare tumor at an unusual site. Case series from a single institution. Arq Gastroenterol. 2013;50(1):3–9.

    Article  PubMed  Google Scholar 

  26. Carter JT, Grenert JP, Rubenstein L, Stewart L, Way LW. Neuroendocrine tumors of the ampulla of Vater: biological behavior and surgical management. Arch Surg. 2009;144(6):527–31.

    Article  PubMed  Google Scholar 

  27. Jensen RT, Berna MJ, Bingham DB, Norton JA. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer. 2008;113(7 Suppl):1807–43.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Ito S, Ogawa Y, et al. Diagnosis and management of Insulinomas. World J Gastroenterol. 2013;19(6):829–37.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Anderson MA, Carpenter S, Thompson NW, Nostrant TT, Elta GH, Scheiman JM. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol. 2000;95(9):2271–7.

    Article  PubMed  CAS  Google Scholar 

  30. Jurgensen C, Schuppan D, Neser F, Ernstberger J, Junghans U, Stolzel U. EUS-guided alcohol ablation of an Insulinomas. Gastrointest Endosc. 2006;63(7):1059–62.

    Article  PubMed  Google Scholar 

  31. Limmer S, Huppert PE, Juette V, Lenhart A, Welte M, Wietholtz H. Radiofrequency ablation of solitary pancreatic Insulinomas in a patient with episodes of severe hypoglycemia. Eur J Gastroenterol Hepatol. 2009;21(9):1097–101.

    Article  PubMed  Google Scholar 

  32. Huang LC, Poultsides GA, Norton JA. Surgical management of neuroendocrine tumors of the gastrointestinal tract. Oncology. 2011;25(9):794–803.

    PubMed  Google Scholar 

  33. Passaro Jr E, Howard TJ, Sawicki MP, Watt PC, Stabile BE. The origin of sporadic gastrinomas within the gastrinoma triangle: a theory. Arch Surg. 1998;133(1):13–6. discussion 7.

    Article  PubMed  Google Scholar 

  34. Zogakis TG, Gibril F, Libutti SK, Norton JA, White DE, Jensen RT, et al. Management and outcome of patients with sporadic gastrinoma arising in the duodenum. Ann Surg. 2003;238(1):42–8.

    PubMed  PubMed Central  Google Scholar 

  35. Norton JA, Alexander HR, Fraker DL, Venzon DJ, Gibril F, Jensen RT. Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome? Ann Surg. 2004;239(5):617–25. discussion 26.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Klimstra DS, Arnold R, Capella C, et al. Tumors of the endocrine pancreas. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. World Health Organization classification of tumors, Pathology and genetics of tumors of the digestive system. Lyon, France: IARC Press; 2010. p. 322–6.

    Google Scholar 

  37. Hruban RH, Pitman MB, Klimstra DS. Tumors of the pancreas. 6th ed. Washington, DC: Armed Forces Institute of Pathology; 2007. p. 251–304.

    Google Scholar 

  38. Capelli P, Martignoni G, Pedica F, et al. Endocrine neoplasms of the pancreas: pathologic and genetic features. Arch Pathol Lab Med. 2009;133:350–64.

    PubMed  Google Scholar 

  39. Chatzipantelis P, Konstantinou P, Kaklamanos M, Apostolou G, Salla C. The role of cytomorphology and proliferative activity in predicting biologic behavior of pancreatic neuroendocrine tumors; a study by endoscopic ultrasound-guided fine-needle aspiration cytology. Cancer. 2009;117:211–6.

    PubMed  Google Scholar 

  40. Asa SL. Pancreatic endocrine tumors. Mod Pathol. 2011;24 suppl 2:S66–77.

    Article  PubMed  CAS  Google Scholar 

  41. Rindi G, Kloppel G, Alhman H, All Other Frascati Consensus Conference Participants; European Neuroendocrine Tumor Society (ENETS), et al. TNM staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395–401.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  42. Verbeke CS. Endocrine tumours of the pancreas. Histopathology. 2010;56:669–82.

    Article  PubMed  Google Scholar 

  43. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707–12.

    Article  PubMed  Google Scholar 

  44. Adsay V. Ki67 labeling index in neuroendocrine tumors of the gastrointestinal tract and pancreatobiliary tract: to count or not to count is not the question, but rather how to count. Am J Surg Pathol. 2012;36:1743–6.

    Article  PubMed  Google Scholar 

  45. Piani C, Franchi GM, Cappelletti C, et al. Cytological Ki-67 in pancreatic neuroendocrine tumors: an opportunity for pre-operative grading. Endocr Relat Cancer. 2008;15:175–81.

    Article  PubMed  Google Scholar 

  46. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710–5.

    PubMed  CAS  Google Scholar 

  47. Tang LH, Gonen M, Hedvat C, Modlin IM, Klimstra DS. Objective quantification of the Ki67 proliferation index in neuroendocrine tumors of the gastropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol. 2012;36:1761–70.

    Article  PubMed  Google Scholar 

  48. Remes SM, Tuominen VJ, Helin H, Isola J, Arola J. Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices. Am J Surg Pathol. 2012;36:1359–63.

    Article  PubMed  Google Scholar 

  49. Falconi M, Bartsch DK, Kriksson G, Barcelona Consensus Conference participants, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology. 2012;95:120–34.

    Article  PubMed  CAS  Google Scholar 

  50. Pavel M, Baudin E, Couvelard A, Barcelona Consensus Conference Participants, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157–76.

    Article  PubMed  CAS  Google Scholar 

  51. Reynolds I, Healy P, McNamara DA. Malignant tumours of the small intestine. Surgeon. 2014.

    Google Scholar 

  52. Rodrigues G, Prabhu R, Ravi B. Small bowel carcinoid: a rare cause of bowel obstruction. BMJ Case Rep. 2013. doi: 10.1136/bcr-2013-200875.

    Google Scholar 

  53. Landry CS, Brock G, Scoggins CR, McMasters KM, Martin 2nd RC. A proposed staging system for gastric carcinoid tumors based on an analysis of 1,543 patients. Ann Surg Oncol. 2009;16(1):51–60.

    Article  PubMed  Google Scholar 

  54. O’Toole D, Ducreux M, Bommelaer G, Wemeau JL, Bouche O, Catus F, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer. 2000;88(4):770–6.

    Article  PubMed  Google Scholar 

  55. Shen C, Shih YC, Xu Y, Yao JC. Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis. Cancer. 2014;120(13):2039–49.

    Article  PubMed  CAS  Google Scholar 

  56. Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, Talamonti MS. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg. 2009;249(1):63–71.

    Article  PubMed  Google Scholar 

  57. Maggard MA, O'Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg. 2004;240(1):117–22.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med. 1999;340(11):858–68.

    Article  PubMed  CAS  Google Scholar 

  59. Moertel CG, Weiland LH, Nagorney DM, Dockerty MB. Carcinoid tumor of the appendix: treatment and prognosis. N Engl J Med. 1987;317(27):1699–701.

    Article  PubMed  CAS  Google Scholar 

  60. Murray SE, Lloyd RV, Sippel RS, Chen H. Clinicopathologic characteristics of colonic carcinoid tumors. J Surg Res. 2013;184(1):183–8.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Peralta EA. Rare anorectal neoplasms: gastrointestinal stromal tumor, carcinoid, and lymphoma. Clin Colon Rectal Surg. 2009;22(2):107–14.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Shields CJ, Tiret E, Winter DC, International Rectal Carcinoid Study Group. Carcinoid tumors of the rectum: a multi-institutional international collaboration. Ann Surg. 2010;252(5):750–5.

    Article  PubMed  Google Scholar 

  63. Ono A, Fujii T, Saito Y, Matsuda T, Lee DT, Gotoda T, et al. Endoscopic submucosal resection of rectal carcinoid tumors with a ligation device. Gastrointest Endosc. 2003;57(4):583–7.

    Article  PubMed  Google Scholar 

  64. Kwaan MR, Goldberg JE, Bleday R. Rectal carcinoid tumors: review of results after endoscopic and surgical therapy. Arch Surg. 2008;143(5):471–5.

    Article  PubMed  Google Scholar 

  65. Park HW, Byeon JS, Park YS, Yang DH, Yoon SM, Kim KJ, et al. Endoscopic submucosal dissection for treatment of rectal carcinoid tumors. Gastrointest Endosc. 2010;72(1):143–9.

    Article  PubMed  Google Scholar 

  66. Caplin M, Sundin A, Nillson O, Baum RP, Klose KJ, Kelestimur F, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology. 2012;95(2):88–97.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, Department of Surgery, University of Louisville, 315 E. Broadway, #312, Louisville, KY, 40202, USA

    Travis Spaulding B.S. & Robert C. G. Martin II M.D., Ph.D., F.A.C.S.

Authors
  1. Travis Spaulding B.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert C. G. Martin II M.D., Ph.D., F.A.C.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert C. G. Martin II M.D., Ph.D., F.A.C.S. .

Editor information

Editors and Affiliations

  1. Division of Gastrointestinal and Laparoscopic Surgery, Medical University of South Carolina, Charleston, South Carolina, USA

    Katherine A. Morgan

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Spaulding, T., Martin, R.C.G. (2016). Gastrointestinal Neuroendocrine Tumors: Optimal Outcomes and Surgical Management. In: Morgan, K. (eds) Current Controversies in Cancer Care for the Surgeon. Springer, Cham. https://doi.org/10.1007/978-3-319-16205-8_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-16205-8_3

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-16204-1

  • Online ISBN: 978-3-319-16205-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation